Table 1 Patient, disease, and transplant characteristics

Median follow-up (months) [quartiles]

25.9 [24.5–28.1]

26.3 [24.5–28.8]

24.6 [19.6–31.2]

Patient age (years), median (min–max) [IQR]

56.4 (18.1–82.5) [44.9–64.4]

55.8 (18.1–82.5) [44–63.8]

60.8 (20.8–75.7) [51.6–67.2]

Year transplant, median (min–max)

2019 (2010–2021) [2017–2020]

2019 (2010–2021)

2019 (2010–2021)

Cytogenetics

Interm

1192 (69.7%)

1037 (70.1%)

155 (67.1%)

Adverse

519 (30.3%)

443 (29.9%)

76 (32.9%)

Time diagnosis to HSCT (mo), median (min–max) [IQR]

5.1 (1–23.9) [4–6.7]

5.2 (1–23.9) [4.1–6.7]

4.9 (1.3–20.5) [3.5–6.5]

MRD pre transplant

neg

533 (63.2%)

495 (63.5%)

38 (59.4%)

pos

310 (36.8%)

284 (36.5%)

26 (40.6%)

Missing

868

701

167

HT-CI

HT-CI = 0

798 (55.2%)

721 (57.1%)

77 (41.8%)

HT-CI = 1 or 2

304 (21%)

272 (21.6%)

32 (17.4%)

HT-CI ≥ 3

344 (23.8%)

269 (21.3%)

75 (40.8%)

Missing

265

218

47

Karnofsky score

< 90

381 (23.3%)

311 (22%)

70 (31.5%)

≥ 90

1256 (76.7%)

1104 (78%)

152 (68.5%)

Missing

74

65

9

Patient sex

Male

994 (58.1%)

851 (57.5%)

143 (61.9%)

Female

717 (41.9%)

629 (42.5%)

88 (38.1%)

Donor sex

Male

1052 (61.7%)

912 (61.8%)

140 (60.9%)

Female

654 (38.3%)

564 (38.2%)

90 (39.1%)

Missing

5

4

1

Female to male combination

No F → M

1357 (79.4%)

1180 (79.8%)

177 (76.6%)

F → M

352 (20.6%)

298 (20.2%)

54 (23.4%)

Missing

2

2

0

Patient CMV

Neg

367 (21.7%)

313 (21.3%)

54 (23.8%)

Pos

1328 (78.3%)

1155 (78.7%)

173 (76.2%)

Missing

16

12

4

Donor CMV

neg

643 (38.1%)

545 (37.3%)

98 (43.8%)

pos

1043 (61.9%)

917 (62.7%)

126 (56.2%)

Missing

25

18

7

Conditioning

MAC

823 (48.1%)

742 (50.1%)

81 (35.1%)

RIC

888 (51.9%)

738 (49.9%)

150 (64.9%)

Cell source

BM

483 (28.2%)

433 (29.3%)

50 (21.6%)

PB

1228 (71.8%)

1047 (70.7%)

181 (78.4%)